Quarterly report pursuant to Section 13 or 15(d)

Stockholders Equity (Tables)

v3.24.3
Stockholders Equity (Tables)
9 Months Ended
Sep. 30, 2024
Stockholders Equity [Abstract]  
Schedule of Outstanding Warrants to Purchase Common Stock Issued to Stockholders As of September 30, 2024, the Company had the following outstanding warrants to purchase Common Stock issued to stockholders:
Warrant   Issuance Date   Expiration
Date
  Exercise
Price
Per Share
    Number of
Shares of
Common Stock
Underlying
Warrants
 
Public Warrants   IPO (December 13, 2018)   October 28, 2024     115.00       350,000  
2021 Registered Direct Offering Warrants   SPA (July 28, 2021)   January 28, 2027     50.00       281,251  
Merger Warrants   March 15, 2024   January 28, 2027     50.00       216,650  
Private Placement Warrants   March 15, 2024   July 9, 2026     2.31       10,820,850  
Agents Warrants   March 15, 2024   July 9, 2026     2.31       952,381  
                      12,621,132  
Schedule of Fair Value Of The Agents Warrants Using The Black-Scholes Model The Company determined the fair value of the Agents Warrants using the Black-Scholes model as of March 5, 2024. The main assumptions used are as follows:
Underlying value of Common Stock ($)     2.31  
Exercise price ($)     2.31  
Expected volatility (%)     100.6  
Expected terms (years)     2.32  
Risk-free interest rate (%)     4.4  
Schedule of Options Granted to Purchase A summary of options granted to purchase the Company’s Common Stock under the Company’s share option plans is as follows:
    For the Nine Months Ended
September 30, 2024
 
    Number of
Options
    Weighted
Average
Exercise
Price
    Aggregate
Intrinsic
Value
 
Outstanding at the beginning of period     528,112       5.41       72  
Granted     1,567,795       3.63          
Forfeited     (26,808 )     3.96          
Expired     (6,449 )     4.58          
Exercised    
-
     
-
         
Outstanding at the end of period     2,062,650       4.08       22  
Exercisable at the end of period     351,109       5.79          
Weighted average remaining contractual life of outstanding options – years as of September 30, 2024     8.85                  
Schedule of Outstanding Compensation Related Warrants to Purchase Common Stock As of September 30, 2024, the Company had the following outstanding compensation related warrants to purchase Common Stock:
Warrant   Issuance
Date
  Expiration
Date
    Exercise
Price
Per Share
    Number of
Shares of
Common Stock
Underlying
Warrants
 
Private Warrants issued to scientific founders   November 27, 2017    
-
     
-
      298  
Landlord Warrants*   March 15, 2024     January 28, 2027       50.00       25,000  
                          25,298  
(*) See Note 6.
Schedule of Stock-Based Payment Expenses The following table sets forth the total stock-based payment expenses resulting from options granted, included in the statements of operations:
    Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
    2024     2023     2024     2023  
Research and development expenses, net     273       31       336       202  
General and administrative     556       164       747       439  
      829       195       1,083       641